Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Elicera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicera Therapeutics Files a Patent Application for the Development of the Next Generation Oncolytic Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Elicera Therapeutics","sponsor":"Immunicum AB","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"$0.2 million","newsHeadline":"Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Elicera Therapeutics

    Menu

    Elicera Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Elicera Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics

              Details:

              Under the terms of the agreement, Elicera will grant a world-wide non-exclusive license to Immunicum for the purpose of using the viral vector to label immune cells or tumor cells with exogenous antigens for therapeutic purposes.

              Lead Product(s): Ad5PTD

              Therapeutic Area: Oncology Product Name: Ad5PTD

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Immunicum AB

              Deal Size: $0.5 million Upfront Cash: $0.2 million

              Deal Type: Licensing Agreement January 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Elicera Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Elicera Therapeutics Files a Patent Application for the Development of the Next Generation Oncolytic Viruses

              Details:

              ELC-201 is based on an adenovirus that has been genetically engineered to make the treatment suitable to a wide range of cancer, and the patent application further protects the application of two more genetic alterations, giving the drug candidate three modes of action.

              Lead Product(s): ELC-201

              Therapeutic Area: Oncology Product Name: ELC-201

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY